Galectin Therapeutics Non Currrent Assets Other Over Time
| GALT Stock | USD 1.04 0.96 48.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Galectin Therapeutics Performance and Galectin Therapeutics Correlation. Galectin |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galectin Therapeutics. If investors know Galectin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galectin Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.73) | Return On Assets (1.04) | Return On Equity (37.28) |
The market value of Galectin Therapeutics is measured differently than its book value, which is the value of Galectin that is recorded on the company's balance sheet. Investors also form their own opinion of Galectin Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Galectin Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galectin Therapeutics' market value can be influenced by many factors that don't directly affect Galectin Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galectin Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galectin Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galectin Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Non Currrent Assets Other Analysis
Compare Galectin Therapeutics and related stocks such as Madrigal Pharmaceuticals, Viking Therapeutics, and Sarepta Therapeutics Non Currrent Assets Other Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDGL | 82 K | 631 K | 458 K | 1.4 M | 305 K | 54.0 | 54.0 | 301 K | 227 K | 1.9 M | 1.8 M | 797 K | 1.2 M | 1.4 M | 719.9 K |
| SRPT | 100 K | 155 K | 2.8 M | 25 K | 2.8 M | 4.5 M | 4 M | 21.8 M | 107.3 M | 11.8 M | 13 M | 143.3 M | 286.6 M | 292 M | 306.6 M |
| HEPA | 4.2 K | 4.2 K | 4.2 K | 4.2 K | 4.2 K | 51.3 K | 70 K | 63.2 K | 127.8 K | 306.9 K | 285.1 K | 583.3 K | 426.2 K | 364.2 K | 228.6 K |
| PTCT | 297.9 K | 297.9 K | 197.1 K | 149 K | 489 K | 3.1 M | 630 K | 1.2 M | 2.3 M | 30.1 M | 60.6 M | 227.5 M | 48.6 M | 36.2 M | 34.8 M |
| TERN | 335 K | 335 K | 335 K | 335 K | 335 K | 335 K | 335 K | 335 K | 335 K | 719 K | 246 K | 94 K | 37 K | 56 K | 53.2 K |
| AKRO | 20 K | 20 K | 20 K | 20 K | 20 K | 20 K | 20 K | 20 K | 20 K | 29 K | 161 K | 417 K | 108 K | (1.0) | (0.95) |
| DMAC | 0.0 | 3.6 M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 271 K | 271 K | 217 K | 100 K | (40.4 M) | (1.0) | (0.9) | (0.94) |
| MIST | 35 K | 35 K | 35 K | 35 K | 35 K | 35 K | 35 K | 35 K | 30 K | (929 K) | (1.3 M) | (926 K) | (2.7 M) | (2.4 M) | (2.3 M) |
| MCRB | (266 K) | (266 K) | (266 K) | 68 K | 1.8 M | 1.5 M | 1.4 M | 1.5 M | 113 K | 1.4 M | 1.4 M | 14.6 M | 10.5 M | 50.9 M | 53.5 M |
| IKT | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 2.9 K | 15.8 M | 15.8 M | 15.8 M | 18.2 M | 9.2 M |
| ONCY | 1.0 | 392.1 K | 409.2 K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 998 K | 998 K | (1.0) | (0.95) |
| ETNB | 53 K | 53 K | 53 K | 53 K | 53 K | 53 K | 53 K | 53 K | 53 K | 72 K | 706 K | 290 K | 289 K | 396 K | 331.1 K |
| PLRX | 536 K | 536 K | 536 K | 536 K | 536 K | 536 K | 536 K | 536 K | 536 K | 3.1 M | 451 K | 838 K | 394 K | 1.9 M | 957.1 K |
| ACLX | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 3.2 M | 5.5 M | 4.6 M | 11.8 M | 12.4 M |
| STOK | 56 K | 56 K | 56 K | 56 K | 56 K | 56 K | 56 K | 56 K | 204 K | 205 K | 205 K | 569 K | 569 K | 654.4 K | 373.5 K |
Galectin Therapeutics and related stocks such as Madrigal Pharmaceuticals, Viking Therapeutics, and Sarepta Therapeutics Non Currrent Assets Other description
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.My Equities
My Current Equities and Potential Positions
| Galectin Therapeutics | GALT |
| Classification | Israel Wall Street |
| Location | Georgia; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.04
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.